Bearish
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing
Indaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantia...